Patents by Inventor Larry C. Ford

Larry C. Ford has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5733568
    Abstract: Micro-encapsulated lactobacilli bacteria are orally administered to mammals, including humans, to treat or prevent antibiotic associated or other chronic or acute diarrhea. Micro-encapsulated lactobacilli bacteria are topically administered to the skin to treat or prevent recurrent skin infections, and are administered intra-vaginally to treat or prevent vaginal yeast infections.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: March 31, 1998
    Assignee: Lafor Laboratories Limited
    Inventor: Larry C. Ford
  • Patent number: 5635202
    Abstract: Micro-encapsulated lactobacilli bacteria are orally administered to mammals, including humans, to treat or prevent antibiotic associated or other chronic or acute diarrhea. Micro-encapsulated lactobacilli bacteria are topically administered to the skin to treat or prevent recurrent skin infections, and are administered intra-vaginally to treat or prevent vaginal yeast infections.
    Type: Grant
    Filed: March 13, 1996
    Date of Patent: June 3, 1997
    Assignee: Lafor Laboratories Limited
    Inventor: Larry C. Ford
  • Patent number: 5633012
    Abstract: Micro-encapsulated lactobacilli bacteria are orally administered to mammals, including humans, to treat or prevent antibiotic associated or other chronic or acute diarrhea. Micro-encapsulated lactobacilli bacteria are topically administered to the skin to treat or prevent recurrent skin infections, and are administered intra-vaginally to treat or prevent vaginal yeast infections.
    Type: Grant
    Filed: April 5, 1996
    Date of Patent: May 27, 1997
    Assignee: Lafor Laboratories Limited
    Inventor: Larry C. Ford
  • Patent number: 5614209
    Abstract: Micro-encapsulated lactobacilli bacteria are orally administered to mammals, including humans, to treat or prevent antibiotic associated or other chronic or acute diarrhea. Micro-encapsulated lactobacilli bacteria are topically administered to the skin to treat or prevent recurrent skin infections, and are administered intra-vaginally to treat or prevent vaginal yeast infections.
    Type: Grant
    Filed: March 13, 1996
    Date of Patent: March 25, 1997
    Assignee: Lafor Laboratories Limited
    Inventor: Larry C. Ford
  • Patent number: 5466463
    Abstract: A vaginal suppository or other type of vaginal pessary such as cream, foam or ointment, which contains as its active ingredients at least one pharmaceutically acceptable, topically safe antimicrobial agent, such as an agent selected from the group of benzalkonium chloride, cetylpyridinium chloride, chlorhexidine gluconate and povidone iodine, imidiazolidinyl urea and diazolidinyl urea and a viable colony of micro-encapsulated lactobacilli bacteria. The viable lactobacilli are included in the suppository in micro encapsulated form, which protects the bacteria during storage of the suppository from the action of the bacteriocidal agent. When exposed to the vaginal milieu the micro encapsulation breaks down sufficiently to release the lactobacili bacteria. The lactobacilli bacteria serve to maintain or re-establish a healthy lactobacilli based flora on the vaginal wall, and excrete hydrogen peroxide and other bactericidins which suppress abnormal flora conditions that promote infections.
    Type: Grant
    Filed: September 7, 1994
    Date of Patent: November 14, 1995
    Assignee: Lafor Laboratories Limited
    Inventor: Larry C. Ford
  • Patent number: 5264619
    Abstract: Compounds having the formula (i), (ii) and (iii), ##STR1## where R is H, alkyl of 1 to 6 carbons, or CO--R.sub.2 where R.sub.2 is alkyl of 1 to 6 carbons; R.sub.1 is H, CH.sub.3, or (CH.sub.2).sub.m --CH.sub.3 ; n is an integer having the values of 2 to 10, m is an integer having the values of 1 to 6, have anti-androgen activity on secondary androgen receptor sites. The compounds are useful for treating mammals, including humans afflicted with acne, male pattern baldness, adhesions and keloids. The compounds are also effective for treating other diseases or conditions which are related to androgen receptors, such as undesirable formation of breast capsules in females after breast augmentation surgery, osteoarthritis and symptoms of Alzheimer's disease. The compounds also have inhibitory effect on the metabolism of certain microorganisms and fungi of the kind, the metabolism of which is normally known to be controllable by anti-androgen compounds.
    Type: Grant
    Filed: January 15, 1993
    Date of Patent: November 23, 1993
    Assignee: Lafor Laboratories Limited
    Inventor: Larry C. Ford
  • Patent number: 4255517
    Abstract: A new and improved assay for the determination of the enzyme lysozyme in biological samples which utilizes a plate assay based upon the bacterium Micrococcus lysodiekticus is described. The assay utilizes a novel composition for the assay medium which results in a reduction in assay incubation time to the point that the assay is complete after one-half hour. This reduction in time is achieved in part by the utilization of organic buffers in the assay medium and in part by the reduction of the ionic strength of the assay medium. by the use of this assay a novel technique for determining the integrity of the amniochorial membrane and maturity of fetal lungs are described.
    Type: Grant
    Filed: February 2, 1979
    Date of Patent: March 10, 1981
    Inventor: Larry C. Ford